Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Epidemiology/Health Services/Psychosocial Research

Impact of Fasting Plasma Glucose Levels on Gastric Cancer Incidence in a General Japanese Population

The Hisayama Study

  1. Hajime Yamagata, MD1,
  2. Yutaka Kiyohara, MD1,
  3. Shotaro Nakamura, MD1,
  4. Michiaki Kubo, MD1,
  5. Yumihiro Tanizaki, MD1,
  6. Takayuki Matsumoto, MD1,
  7. Keiichi Tanaka, MD1,
  8. Isao Kato, MD1,
  9. Tomoko Shirota, MD2 and
  10. Mitsuo Iida, MD1
  1. 1Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  2. 2Department of Health Promotion, School of Health and Nutrition Sciences, Nakamura-Gakuen University, Fukuoka, Japan
  1. Address correspondencereprint requests to Hajime Yamagata, MD, Department of MedicineClinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: yamagen{at}intmed2.med.kyushu-u.ac.jp
Diabetes Care 2005 Apr; 28(4): 789-794. https://doi.org/10.2337/diacare.28.4.789
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

The Hisayama Study

Abstract

OBJECTIVE—Several studies have shown associations between diabetes and various types of cancer other than gastric cancer. The aim of this cohort study was to evaluate the impact of fasting plasma glucose (FPG) levels on gastric cancer occurrence.

RESEARCH DESIGN AND METHODS—A total of 2,466 Japanese subjects aged ≥40 years were stratified into three groups according to FPG tertiles (<5.3 mmol/l, low FPG; 5.3–5.8 mmol/l, modest FPG; >5.8 mmol/l, high FPG) and followed up prospectively for 9 years.

RESULTS—During the follow-up, 66 subjects experienced gastric cancer. In men, the age-adjusted incidences were significantly higher in the modest-FPG (7.0 per 1,000 person-years, P < 0.05) and high-FPG (7.2, P < 0.05) groups than in the low-FPG group (2.2). In women, the high-FPG group also had a significantly higher age-adjusted incidence of gastric cancer compared with the low-FPG group (2.5 vs. 0.8, P < 0.05). The multivariate analysis with Cox’s proportional hazards model revealed that the risks of gastric cancer in the modest-FPG (relative risk [RR] 2.3 [95% CI 1.1–5.0]) and high-FPG (3.1 [1.5–6.4]) groups were significantly higher than that in the low-FPG group, even after adjusting for other comprehensive risk factors, including Helicobacter pylori status, smoking, and dietary factors. However, this FPG-cancer association was observed only among H. pylori–seropositive subjects.

CONCLUSIONS—Our findings suggest that a modest increase in FPG is a risk factor for gastric cancer and that hyperglycemia is a possible cofactor increasing the risk posed by Helicobacter pylori infection.

  • FPG, fasting plasma glucose

The Japanese population is characterized by a high morbidity from gastric cancer and a high prevalence of Helicobacter pylori infection, especially in middle-aged and elderly individuals (1). We have previously reported a significant relationship between infection with H. pylori and a subsequent occurrence of gastric cancer for men in a general Japanese population (2). However, only a small percentage of people with H. pylori infection develop gastric cancer, indicating that H. pylori cannot be the only etiologic factor of gastric cancer; other cofactors must affect the relationship between H. pylori infection and the development of gastric cancer.

On the other hand, a possible association between diabetes and an increase in mortality from malignant neoplasm has been discussed for many years (3). Several prospective cohort studies have examined the associations between diabetes and total cancers (4–7). Among them, three studies have demonstrated that diabetes is associated with an excess risk for all cancers (4–6), while another study could not confirm a positive association between diabetes and total cancer (7). Several recent studies have shown associations between diabetes and cancer in the pancreas (8, 9), liver (8, 10), and large bowel (11, 12). To our knowledge, none of the previous studies evaluated the impact of hyperglycemia on the development of gastric cancer.

In the present investigation, we prospectively examined the relationship between fasting plasma glucose (FPG) levels and gastric cancer occurrence in a general Japanese population, taking H. pylori infection as well as other comprehensive risk factors into consideration.

RESEARCH DESIGN AND METHODS

The Hisayama study is a prospective epidemiological study of ongoing cardiovascular disease and malignancy in Hisayama Town, a suburban community adjacent to Fukuoka City, a metropolitan area on Kyushu Island in Japan. The study design and characteristics of the subject population have been described in detail elsewhere (2, 13, 14). In 1988, 2,742 residents aged ≥40 years (80.1% of the total population in that age population) underwent a screening examination. After excluding 132 individuals with a prior history of gastrectomy or gastric cancer, 141 individuals who had eaten breakfast on the day of the screening examination, and 3 individuals who died during the examination period, a total of 2,466 subjects were enrolled in the present study.

Follow-up survey

The population was followed up for 9 years, from December 1988 through November 1997, by repeated health check-ups every 1–2 years. For subjects who did not undergo regular check-ups or who moved out of the town, the health status was checked every year by mail or telephone. In addition, a daily monitoring system was established by the study team and local physicians or members of the Division of Health and Welfare of the town. To identify any occurrence of gastric cancer in the cohort, we reviewed radiographic, endoscopic, and biopsy records for the stomach at local clinics or general hospitals within and around Hisayama Town. We also checked all the records of the annual mass screenings for gastric cancer by means of barium X-ray examination. Further, to find any concealed gastric cancer, autopsy examinations were performed on 212 (79.1%) of a total of 268 subjects who died during the follow-up period. The diagnosis of gastric cancer was confirmed by histological examination of resected specimens obtained by gastrectomy, endoscopic mucosal resection, or autopsy.

During the follow-up period, only 1 subject was lost, and 71 gastric cancers were identified in 66 subjects (48 men and 18 women); 5 subjects (7.6%) each had two gastric cancers, and 2 concealed cases (3.0%) were diagnosed at autopsy. The time interval from the baseline screening to the diagnosis of gastric cancer ranged from 0.5 to 8.7 years (mean 5.0 years).

Laboratory testing and risk factor measurement

For the measurement of FPG levels, blood was drawn from an antecubital vein using vacutainer tubes with heparin, EDTA, and fluoridated natrium. The blood sampling was undertaken between 8:00 a.m. and 10:30 a.m. after an overnight fast of at least 12 h. Plasma glucose was determined by the glucose-oxidase method. Diabetes was determined by either a 75-g oral glucose tolerance test (1998 World Health Organization criteria), FPG levels (≥7.0 mmol/l), or a medical history of diabetes. The numbers of subjects with diabetes diagnosed by each type of diagnosis were 294, 4, and 9, respectively. Based on the distribution of FPG levels, subjects were classified into tertile groups: low FPG (<5.3 mmol/l), modest FPG (5.3–5.8 mmol/l), and high FPG (>5.8 mmol/l).

Serum IgG antibodies to H. pylori were measured by means of a quantitative enzyme immunoassay using a commercial kit (HM-CAP; Enteric Products, Westbury, NY). The assay values were interpreted as positive, negative, or indeterminate, based on the manufacturer’s instructions. Serum cholesterol levels were determined by an enzymatic autoanalyzer (TBA-80S; Toshiba, Tokyo, Japan). Height and weight were measured with the subject in light clothes without shoes, and the BMI (kg/m2) was calculated. Dietary factors were obtained by a semiquantitative food frequency method that was previously validated in a prior study (15). A self-administered questionnaire concerning food intake over the previous year, which included 70 food items, was completed before the start of the study by each participant and was checked by experienced dietitians and nutritionists by showing food models of actual size in the survey. The average daily nutrient intakes, including total energy, total fat, salt, vitamin A, vitamin B1, vitamin B2, vitamin C, and dietary fibers, were calculated using the 4th revision of the Standard Tables of Food Composition in Japan (16), and the nutritional elements were adjusted for energy intake using the method of Willet and Stampfer (17). Information about smoking habits, alcohol intake, and history of peptic ulcer disease were obtained by means of a questionnaire administered to each subject, and the former two items were categorized as in current use or not in current use.

Statistical analysis

The SAS computer package (18) was used for all statistical analyses. Mean values of the possible risk factors were adjusted for age by the covariance method and were compared among tertile groups of FPG using Fisher’s least significant difference method. The frequencies of risk factors were compared by the Mantel-Haenszel χ2 test after adjusting for age by the direct method. The incidence of gastric cancer was calculated by the person-year method, and its differences among groups with different FPG levels were analyzed by means of Cox’s proportional hazards model (19). The risk factor–adjusted relative risks (RRs) were also estimated using Cox’s proportional hazards model and are expressed together with 95% CIs. In the multivariate analysis, we used a stepwise method, setting the significance level for entry and keeping it at 0.1. Only 19 subjects who did not develop gastric cancer dropped out due to missing values in the covariates, while no case with gastric cancer dropped out of the analysis. For age adjustment, all study subjects were used as a standard population.

This study was conducted with the approval of the ethics committee of Kyushu University, and written informed consent for medical research was obtained from the study participants.

RESULTS

Table 1 compares the age-adjusted mean values or frequencies of possible risk factors for gastric cancer among the three FPG groups by sex. In men and women, the mean age increased significantly with an increase in FPG levels, and diabetes was found most frequently in the high-FPG group. Similarly, mean values of BMI and total cholesterol and frequency of alcohol intake in both sexes increased significantly with increases in FPG levels. The frequency of smoking habits in men decreased significantly with elevated FPG levels. The frequency of H. pylori infection and history of peptic ulcer disease and mean values of dietary factors were not found to be related to FPG levels in either sex.

As shown in Table 2, the age-adjusted incidence of gastric cancer of 5.6 per 1,000 person-years for men was significantly higher than that of 1.3 per 1,000 person-years for women. In men, the age-adjusted incidence was significantly higher in the modest-FPG (7.0, P < 0.05) and high-FPG (7.2, P < 0.05) groups than in the low-FPG (2.2) group. In women, the high-FPG group also had a significantly higher age-adjusted incidence of gastric cancer (2.5, P < 0.05) compared with that of the low-FPG group (0.8). The age- and sex-adjusted risks of gastric cancer in the modest-FPG (RR 2.3 [95% CI 1.1–5.1]) and high-FPG (3.0 [1.5–6.4]) groups were significantly higher than those in the low-FPG group (Fig. 1). These associations remained unchanged even after adjustment for age, sex, BMI, serum cholesterol, H. pylori seropositivity, smoking habits, alcohol intake, history of peptic ulcer disease, and dietary factors, including intake of total energy, total fat, salt, vitamin A, vitamin B1, vitamin B2, vitamin C, and dietary fibers. In addition, we performed the same analysis with all subjects except for those who developed gastric cancer in the first 2 years of the follow-up period to decrease the influence of the concealed gastric cancers at baseline. As a result, the age- and sex-adjusted RR of gastric cancer was 2.2 (95% CI 0.9–4.9) in the modest-FPG group and 2.9 (1.3–6.3) in the high-FPG group. The magnitude of the cancer risk in the modest- and high-FPG groups was almost the same as that obtained in the analysis of all subjects, although no statistically significant difference was found in the modest-FPG group, probably due to the small number of cases.

The seroprevalence of H. pylori was 66.6% for all subjects, 77.3% for those with gastric cancer, and 66.3% for the subjects who did not develop gastric cancer. We then compared the risk of gastric cancer among FPG groups under stratification by H. pylori status (Fig. 2). Among H. pylori–positive subjects, the age- and sex-adjusted risks of gastric cancer were significantly higher in the modest-FPG (RR 3.5 [95% CI 1.3–9.5]) and high-FPG (4.2 [1.6–11.1]) groups than in the low-FPG group, whereas no such differences were found in H. pylori–negative subjects.

CONCLUSIONS

Our findings indicate a positive association between elevated FPG levels and gastric cancer incidence in men and women, an association that remains significant even after adjusting for other risk factors such as age, sex, BMI, serum cholesterol, H. pylori seropositivity, smoking habits, alcohol intake, history of peptic ulcer disease, and dietary factors. The risk of gastric cancer was found to be increased not only in the high-FPG group, of which approximately one-third was diagnosed as diabetic, but also in the modest-FPG group, in which only a small number of subjects fulfilled the diagnostic criteria of diabetes. These results suggest that subjects with high FPG levels may have an increased risk of developing gastric cancer, even if they have not developed diabetes. In addition, a stratified analysis showed increased FPG levels to be an independent risk factor for gastric cancer only among H. pylori–seropositive subjects; no such risk was observed among H. pylori–seronegative subjects.

In this study, the age-adjusted incidence of gastric cancer was 5.6 per 1,000 person-years for men and 1.3 for women, which is higher than that found in previous studies in Japan (0.7–2.0 per 1,000 person-years for men and 0.3–0.7 for women) (20–23). This discrepancy seems to be due to differences in the study design as well as in the age structures or regions examined. The previous studies were registration studies, while ours was a prospective cohort study in which we carried out an intensive and accurate survey of gastric cancer, including autopsy examination of 79% of the deceased subjects to find any concealed gastric cancer. It is therefore supposed that our study results reflect the actual cancer incidence in the Japanese population.

The mechanisms for increased risk of gastric cancer in hyperglycemia remain obscure. One possible explanation is that hyperglycemia and its related conditions act directly as a carcinogenic factor. Dandona et al. (24) have demonstrated in a clinical study with diabetic subjects and healthy volunteers that diabetes is associated with increased production of reactive oxygen species and greater oxidative damage to DNA. In an experimental study, high glucose itself was shown to induce DNA damage (25). Thus, it is possible that increased production of reactive oxygen species or high glucose itself contributes to DNA damage, which may lead to mutational changes in oncogenes and tumor suppressor genes, and thereby to the development of gastric cancer.

Another possible explanation is that hyperinsulinemia is related to gastric carcinogenesis. Patients with hyperglycemia are prone to insulin resistance, which leads to higher levels of blood insulin. McKeown-Eyssen (26) and Giovannucci (27, 28) showed in epidemiological and experimental studies that hyperinsulinemia is involved in colonic carcinogenesis. These investigators independently hypothesized that well-specified risk factors for colorectal cancer, such as obesity, physical inactivity, alcohol consumption, or a typical western diet, contribute to insulin resistance. Ogihara et al. (29) have demonstrated that insulin enhances the stimulatory effects of epidermal growth factor on the proliferation of cultured gastric epithelial cells obtained from the guinea pig. It can be speculated that an increase in cell proliferation predisposes the gastric mucosa to genetic or epigenetic alterations and, therefore, to carcinogenesis (30, 31).

Finally, it is postulated that gastric cancer and hyperglycemia share common genetic or environmental risk factors. However, no common genetic background or common provisional risk factor other than age has been identified to date. Furthermore, that hypothesis cannot be supported by our results; we failed to show any significant correlation of FPG levels with H. pylori status or with dietary factors. Further, although smoking habits have been presumed to be a risk factor for gastric cancer (32), the frequency of smoking habits in men was rather low in the high- and modest-FPG groups relative to that in the low-FPG group.

Based on numerous epidemiologic and experimental studies, H. pylori has been regarded to be a definite risk factor for gastric cancer (2, 33). Although the precise pathogenetic role of H. pylori in gastric carcinogenesis remains unclear, it has been clarified that this organism contributes to modifications in epithelial cell proliferation (34, 35), which may be the initiating event in a cascade culminating in the development of gastric cancer. However, an increased risk of gastric cancer by H. pylori infection notwithstanding, the majority of H. pylori–infected subjects do not develop gastric cancer. As such, H. pylori is not the absolute oncogenic factor for gastric cancer, and there must be other critical cofactors contributing to the risk posed by H. pylori infection. Our stratified analysis showed increased FPG levels to be a significant risk factor for gastric cancer only among H. pylori–seropositive subjects; this link was not observed among H. pylori–seronegative subjects. This result indicates that hyperglycemia is a possible cofactor increasing the risk posed by H. pylori infection. In a clinical study, Acbay et al. (36) demonstrated that H. pylori gastritis enhances glucose- and meal-stimulated insulin release, probably by increasing gastrin secretion. Thus, the enhanced effect of hyperglycemia on the H. pylori–cancer association may be explained partially by hyperinsulinemia. Another possible explanation for this phenomenon may be that hyperglycemia affects H. pylori and its infection status or stimulates its carcinogenic effects. However, the association between H. pylori infection and diabetes is controversial in the literature. A higher prevalence of H. pylori infection in diabetic than in control subjects has been reported in some studies (37, 38), whereas other studies have found no association between H. pylori and diabetes (39, 40). In this study, we found no significant correlation between FPG levels and H. pylori status. It may be speculated that increased reactive oxygen–related damage to DNA and genetic or epigenetic alterations in gastric mucosa induced by hyperglycemia or associated hyperinsulinemia encourage a modifying effect of H. pylori on epithelial cell proliferation, which may be the initial step in a cascade of gastric carcinogenesis. Given the range of findings, this hypothesis requires further consideration.

Several limitations of our study should be discussed. The primary limitation of our study, which is typical of most prospective studies, is that changes in other potentially confounding factors for the development of gastric cancer were not reassessed over time in our subjects. It is therefore possible that as a result of treatment for diabetes, greater modification of other risk factors occurred in diabetic than in nondiabetic subjects. In our subjects, however, the risk of gastric cancer was increased even in association with pre-diabetic hyperglycemia, which is not subject to medical treatment. In addition, the carcinogenic effects of risk factors usually continue for a long period (41–43). Thus, bias of this kind was considered to be small in the present study.

A second limitation is that an average follow-up time of 5 years does not account for the much longer latency or induction period of gastric cancer. Accordingly, we cannot eliminate the possibility that there were concealed gastric cancers that had already developed by the time of the baseline examination, though this limitation is a common problem for a large majority of other registration studies of gastric cancer. However, the prevalence of gastric cancer in healthy subjects has been found to be low (0.12%) in a nationwide mass screening in Japan (44). In addition, our analysis of all subjects except for those who developed gastric cancer in the first 2 years of the follow-up period produced results similar to those obtained from our analysis of all subjects. We therefore believe that concealed cancers were rare at the baseline examination and that the influence of this bias is small.

The final limitation is that only a small number of gastric cancer cases developed in our cohort, indicating a high possibility of bias in the results. Nonetheless, we believe that the findings of our study represent an accurate incidence of gastric cancer and its association with hyperglycemia, since we performed the study using a highly accurate method for determining all gastric cancer cases.

In conclusion, we found the elevation of FGP levels to be a significant risk factor for gastric cancer in men and women. The contribution of FPG to the subsequent occurrence of gastric cancer was significant in H. pylori–seropositive subjects and not in H. pylori–seronegative subjects. These findings suggest that some interaction between hyperglycemia and H. pylori infection contributes to the development of gastric cancer or that hyperglycemia is a possible cofactor increasing the risk posed by H. pylori infection. Further study is necessary to clarify the pathogenetic role of hyperglycemia as well as of H. pylori infection and their interaction in gastric carcinogenesis.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Age- and sex-adjusted (□) and multivariate-adjusted (▪) RR of gastric cancer of the modest-FPG (5.3–5.8 mmol/l) and high-FPG (>5.8 mmol/l) groups compared with that of the low-FPG (<5.3 mmol/l) group. In the multivariate analysis, the RR is adjusted for age, sex, BMI, serum cholesterol, H. pylori seropositivity, smoking habits, alcohol intake, history of peptic ulcer disease, and dietary factors (intake of total energy, total fat, salt, vitamin A, vitamin B1, vitamin B2, vitamin C, and dietary fibers) using stepwise Cox’s proportional hazards model.

Figure 2—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2—

Age- and sex-adjusted RR of gastric cancer of the modest (5.3–5.8 mmol/l) and high-FPG (>5.8 mmol/l) groups compared with that of the low-FPG (<5.3 mmol/l) group under stratification by H. pylori status. □, H. pylori seronegative; ▪, H. pylori seropositive.

View this table:
  • View inline
  • View popup
Table 1—

Age-adjusted mean values or frequencies of risk factors for gastric cancer according to fasting plasma glucose levels by sex

View this table:
  • View inline
  • View popup
Table 2—

Age-adjusted incidence of gastric cancer according to FPG levels

Acknowledgments

This study was supported in part by a grant-in-aid for scientific research (C:13670370) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted January 10, 2005.
    • Received July 29, 2004.
  • DIABETES CARE

References

  1. ↵
    The EUROGAST Study Group: An international association between Helicobacter pylori infection and gastric cancer. Lancet 341: 1359–1362, 1993
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Yamagata H, Kiyohara Y, Aoyagi K, Kato I, Iwamoto H, Nakayama K, Shimizu H, Tanizaki Y, Arima H, Shinohara N, Kondo H, Matsumoto T, Fujishima M: Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama study. Arch Int Med 160:1962–1968, 2000
    OpenUrl
  3. ↵
    Kessler II: Cancer and diabetes mellitus: a review of the literature. J Chron Dis 23:579–600, 1971
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Steenland K, Nowlin S, Palu S: Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 4:807–811, 1995
    OpenUrlAbstract
  5. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J: Post-load plasma glucose and cancer mortality in middle-aged men and women: 12-year follow-up findings of Chicago Heart Association Detection Project in Industry. Am J Epidemiol 131:254–262, 1990
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Eschwege E, Charles MA, Simon D, Thibult N, Balkau B: From policemen to policies: what is the future for 2-h glucose? The Kelly West Lecture, 2000. Diabetes Care24:1945–1950, 2001
  7. ↵
    Smith GD, Egger M, Shipley MJ, Marmot MG: Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 136:1110–1114, 1992
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH: Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360–1365, 1997
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Everhart J, Wright D: Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 273:1605–1609, 1995
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, Wolk A, McLaughlin JK, Fraumeni JF Jr: Excess risk of primary liver cancer in patient with diabetes mellitus. J Natl Cancer Inst 88:1472–1477, 1996
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E: Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 91:542–547, 1999
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Nilsen TL, Vatten LJ: Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 84:417–422, 2001
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Katsuki S: Epidemiological and clinicopathological study on cerebrovascular disease in Japan. Prog Brain Res 21B:64–89, 1966
    OpenUrl
  14. ↵
    Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Nomiyama K, Ohmori S, Yoshitake T, Shinkawu A, Hasuo Y, Fujishima M: Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama study. Diabetologia 36:1198–1203, 1993
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Shirota T, Yoshizumi E. Accuracy of nutritional survey using the simple method. Jpn J Public Health (in Japanese)37:100–108, 1990
    OpenUrl
  16. ↵
    Resources Council of the Science and Technology Agency: Standard Tables of Food Composition in Japan. 4th ed. Tokyo, Ministry of Finance Printing Bureau, 1982 (in Japanese)
  17. ↵
    Willet W, Stampfer MJ: Total energy intake: implications for epidemiologic analysis. Am J Epidemiol 124:17–27, 1986
    OpenUrlFREE Full Text
  18. ↵
    SAS/STAT User’s Guide. Version 6. Cary, NC, SAS Institute, 1989
  19. ↵
    Cox DR: Regression models and life-tables. J R Stat Soc (Series B) 34:187–220, 1972
    OpenUrl
  20. ↵
    The Research Group for Population-based Cancer Registration in Japan: Cancer incidence in Japan, 1985–89: re-estimation based on data from eight population-based cancer registries. Jpn J Clin Oncol 28:54–67, 1998
    OpenUrlAbstract/FREE Full Text
  21. Kaneko S, Yoshimura T: Time trend analysis of gastric cancer incidence in Japan by histological types, 1975–1989. Br J Cancer84:400–405, 2001
  22. Lambert R, Guilloux A, Oshima A, Pompe-Kirn V, Bray F, Parkin M, Ajiki W, Tsukuma H: Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 97:811–818, 2002
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Nishino Y, Suzuki Y, Ohmori K, Hozawa A, Ogawa K, Kuriyama S, Tsubono Y, Shibuya D, Tsuji I, Fukao A, Hisamichi S: Cancer incidence profiles in the Miyagi Cohort Study. J Epidemiol 14(Suppl. 1):S7–S11, 2004
  24. ↵
    Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, Nicotera T: Oxidative damage to DNA in diabetes mellitus. Lancet 347:444–445, 1996
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Lorenzi M, Montisano DF, Toledo S, Barrieux A: High glucose induces DNA damage in cultured human endothelial cells. J Clin Invest 77:322–325, 1986
  26. ↵
    McKeown-Eyssen G: Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 3:687–695, 1994
    OpenUrlAbstract
  27. ↵
    Giovannucci E: Insulin and colon cancer. Cancer Causes Control 6:164–179, 1995
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Giovannucci E: Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 131 (11 Suppl.):3109S–3120S, 2001
  29. ↵
    Ogihara S, Yamada M, Saito T, Shono M, Rokutan K: Insulin potentiated mitogenic effect of epidermal growth factor on cultured guinea pig gastric mucous cells. Am J Physiol 271:G104–G112, 1996
  30. ↵
    Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE: Increased cell division as a cause of human cancer. Cancer Res 50:7415–7421, 1990
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Farber E: Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res 55:3759–3762, 1995
    OpenUrlFREE Full Text
  32. ↵
    Inoue M, Tajima K, Yamamura Y, Hamajima N, Hirose K, Nakamura S, Kodera Y, Kito T, Tominaga S: Influence of habitual smoking on gastric cancer by histologic subtype. Int J Cancer 81:39–43, 1999
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–789, 2001
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Anti M, Armuzzi A, Gasbarrini A, Gasbarrini G: Importance of changes in epithelial cell turnover during Helicobacter pylori infection in gastric carcinogenesis. Gut 43(Suppl. 1):S27–S32, 1998
  35. ↵
    Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 295:683–686, 2002
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Acbay O, Celik AF, Gundogdu S: Does Helicobacter pylori-induced gastritis enhance food-stimulated insulin release? Dig Dis Sci 41:1327–1331, 1996
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    Oldenburg B, Diepersloot RJ, Hoekstra JB: High seroprevalence of Helicobacter pylori in diabetes mellitus patients. Dig Dis Sci 41:458–461, 1996
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    Gentile S, Turco S, Oliviero B, Torella R: The role of autonomic neuropathy as a risk factor of Helicobacter pylori infection in dyspeptic patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 42:41–48, 1998
    OpenUrlCrossRefPubMed
  39. ↵
    Gasbarrini A, Ojetti V, Pitocco D, De Luca A, Franceschi F, Candelli M, Sanz Torre E, Pola P, Ghirlanda G, Gasbarrini G: Helicobacter pylori infection in patients affected by insulin-dependent diabetes mellitus. Eur J Gastroenterol Hepatol 10:469–472, 1998
    OpenUrlPubMedWeb of Science
  40. ↵
    Xia HH, Talley NJ, Kam EP, Young LJ, Hammer J, Horowitz M: Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 96:1039–1046, 2001
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Inoue M, Tajima K, Hirose K, Kuroishi T, Gao CM, Kitoh T: Life-style and subsite of gastric cancer: joint effect of smoking and drinking habits. Int J Cancer 56:494–499, 1994
    OpenUrlPubMedWeb of Science
  42. Hansson LE, Nyren O, Bergstrom R, Wolk A, Lindgren A, Baron J, Adami HO: Diet and risk of gastric cancer: a population-based case-control study in Sweden. Int J Cancer 55:181–189, 1993
    OpenUrlPubMedWeb of Science
  43. ↵
    Hansson LE, Baron J, Nyren O, Bergstrom R, Wolk A, Lindgren A, Adami HO: Early-life risk indicators of gastric cancer: a population-based case-control study in Sweden. Int J Cancer 57:32–37, 1994
    OpenUrlPubMedWeb of Science
  44. ↵
    Hisamichi S: Screening for gastric cancer. World J Surg 13:31–37, 1989
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 28 (4)

In this Issue

April 2005, 28(4)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Fasting Plasma Glucose Levels on Gastric Cancer Incidence in a General Japanese Population
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Impact of Fasting Plasma Glucose Levels on Gastric Cancer Incidence in a General Japanese Population
Hajime Yamagata, Yutaka Kiyohara, Shotaro Nakamura, Michiaki Kubo, Yumihiro Tanizaki, Takayuki Matsumoto, Keiichi Tanaka, Isao Kato, Tomoko Shirota, Mitsuo Iida
Diabetes Care Apr 2005, 28 (4) 789-794; DOI: 10.2337/diacare.28.4.789

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Impact of Fasting Plasma Glucose Levels on Gastric Cancer Incidence in a General Japanese Population
Hajime Yamagata, Yutaka Kiyohara, Shotaro Nakamura, Michiaki Kubo, Yumihiro Tanizaki, Takayuki Matsumoto, Keiichi Tanaka, Isao Kato, Tomoko Shirota, Mitsuo Iida
Diabetes Care Apr 2005, 28 (4) 789-794; DOI: 10.2337/diacare.28.4.789
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Suboptimal Use of Cardioprotective Drugs in Newly Treated Elderly Individuals With Type 2 Diabetes
  • Disparities in Diabetes Care Between Smokers and Nonsmokers
  • Risk Factors for Mortality Among Patients With Diabetes
Show more Epidemiology/Health Services/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.